Charles River Labs (CRL) Issues Solid Q4 Results; Reaffirms FY12 Outlook

Charles River Laboratories International, Inc. (NYSE: CRL) reported Q4 EPS of $0.69, $0.13 better than the analyst estimate of $0.56. Revenue for the quarter came in at $291 million versus the consensus estimate of $282.76 million.

Charles River Laboratories International, Inc. reaffirmed FY2012 guidance.

For earnings history and earnings-related data on Charles River Laboratories International, Inc. (CRL) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
• Deutsche Bank monitors UK auto sales as Chinese exports grow